Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 125.67

+0.4%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: zax	4/16/2020 6:33:55 PM
	of 961

Gilead Sciences, Inc. (GILD) 76.54 +1.91 (+2.56%) 87.00 +10.46 (13.67%) At Close <------------------> After Hours Gilead stock surges more than 10% on report of promising coronavirus treatment marketwatch.com Gilead Sciences Inc. GILD, +2.55% shares rallied in the extended session Thursday following a report that one of the company's drugs showed promising results in treating COVID-19 patients. Gilead shares surged 12% after hours, following a 2.6% rise to finish Thursday's session at $76.54. Late Thursday, health-care media site Stat reported that nearly all 125 COVID-19 patients in a late-stage clinical study at the University of Chicago treated with Gilead's remdesivir had been discharged after a week of treatment. Stat reported that 113 patients had a severe form of the disease and that two had died. The University of Chicago results, however, are only part of a larger study group that includes 2,400 patients with a severe form of COVID-19 and 1,600 ones with a moderate form. Gilead expects to start releasing results in April. Last week, an analysis published in the New England Journal of Medicine claimed most COVID-19 patients given remdesivir showed clinical improvement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next